Format

Send to

Choose Destination
J Vet Intern Med. 2008 Nov-Dec;22(6):1301-9. doi: 10.1111/j.1939-1676.2008.0190.x. Epub 2008 Sep 24.

Masitinib is safe and effective for the treatment of canine mast cell tumors.

Author information

1
Gulf Coast Veterinary Specialists, Houston, TX, USA. drhahn87@gmail.com

Erratum in

  • J Vet Intern Med. 2009 Jan-Feb;23(1):224. Oglivie, G [corrected to Ogilvie, G].

Abstract

BACKGROUND:

Activation of the KIT receptor tyrosine kinase is associated with the development of canine mast cell tumors (MCT).

HYPOTHESIS/OBJECTIVE:

To evaluate the efficacy of masitinib, a potent and selective inhibitor of KIT, in the treatment of canine MCT.

ANIMALS:

Two hundred and two client-owned dogs with nonmetastatic recurrent or nonresectable grade II or III MCT.

METHODS:

Double-blind, randomized, placebo-controlled phase III clinical trial. Dogs were administered masitinib (12.5 mg/kg/d PO) or a placebo. Time-to-tumor progression (TTP), overall survival, objective response at 6 months, and toxicity were assessed.

RESULTS:

Masitinib increased overall TTP compared with placebo from 75 to 118 days (P = .038). This effect was more pronounced when masitinib was used as first-line therapy, with an increase in the median TTP from 75 to 253 days (P = .001) and regardless of whether the tumors expressed mutant (83 versus not reached [P = .009]) or wild-type KIT (66 versus 253 [P = .008]). Masitinib was generally well tolerated, with mild (grade I) or moderate (grade II) diarrhea or vomiting as the most common adverse events.

CONCLUSIONS AND CLINICAL IMPORTANCE:

Masitinib is safe and effective at delaying tumor progression in dogs presenting with recurrent or nonresectable grade II or III nonmetastatic MCT.

PMID:
18823406
DOI:
10.1111/j.1939-1676.2008.0190.x
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center